Cullinan Therapeutics price target raised to $33 from $28 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Cullinan Therapeutics (CGEM) to $33 from $28 and keeps a Buy rating on the shares after the company announced that the Phase 2b REZILIENT1 trial met its primary endpoint. Pending regulatory discussions with the FDA, Cullinan and Taiho intend to submit for regulatory approval in the U.S. in the second half of 2025, the analyst tells investors in a research note. The firm anticipates zipalertinib could be launched in 2026 with sales of $41M that year, growing to $397M in 2031.